ACAD$22.17
Chart
Performance
Key Stats
AI ACAD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyACADIA Pharmaceuticals shows strong fundamental performance with improving profitability and a solid cash position. Thematic alignment with CNS disorder treatments is positive, though current technical indicators suggest a neutral to slightly cautious short-term outlook. Primarily recommended for investors with a medium to long-term horizon focused on the biotechnology sector.
Thematic
ACADIA Pharmaceuticals is positioned within the growing biotechnology sector, focusing on unmet needs in CNS disorders and rare diseases. Its product pipeline and market focus align with key healthcare trends.
Fundamental
ACADIA Pharmaceuticals demonstrates a strong financial foundation with a significant improvement in profitability and revenue generation. The company has a healthy balance sheet with manageable debt and growing cash reserves.
Technical
ACADIA Pharmaceuticals exhibits mixed technical signals. While the stock is trading above key moving averages, indicating a general upward trend, short-term momentum indicators suggest potential for consolidation or a slight pullback. The price is currently near its 52-week high.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Market Focus: CNS Disorders | 80 |
| Commercialization Success | 70 |
| Partnerships & Collaborations | 75 |
| Regulatory Landscape (Pharma) | 65 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 85 |
| Growth | 90 |
| Balance Sheet Health | 95 |
| Cash Flow | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| Short-Term Indicators | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Improving Earnings Trend
Recent EPS figures show a positive trend: Q4 2024 reported EPS of $0.20 beat estimates by 44.81%, and Q3 2024 reported EPS of $0.20 beat estimates by 12.03%. Q2 2024 also showed a significant beat with reported EPS of $0.10 versus an estimate of $0.05 (113.68% surprise).
Positive P/E Ratio Momentum
The P/E TTM (Trailing Twelve Months) ratio is 16.82, and the company has shown a return to profitability in recent quarters (Q4 2024 and Q3 2024), suggesting potential for future valuation expansion.
Bearish Points (7)
Inconsistent EPS Performance
Despite recent positive surprises, the company reported negative EPS in Q1 2024 (-$0.02 vs. estimate of $0.22, -109.25% surprise) and Q3 2023 ($0.01 vs. estimate of -$0.08, 112.11% surprise). Previous years also show significant net losses.
Negative P/E in Prior Years
The company experienced significant net losses in 2021, 2022, and 2023, resulting in negative P/E ratios (-23.3, -17.9, -62.9 respectively). While profitability has improved, the historical unprofitability presents a valuation risk if future earnings do not stabilize.
Calendar
August 2025
7
Next Earnings Date
H: $0.19
A: $0.14
L: $0.07
H: 272.58M
A: 262.07M
L: 255.90M
Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Seasonals
Price Target
28.95 USD
The 39 analysts offering 1 year price forecasts for ACAD have a max estimate of 39.00 and a min estimate of 15.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in CNS movement disorders, particularly tardive dyskinesia and Parkinson's disease, areas of core focus for ACAD.
Weight: 90
Major competitor in neuropsychiatric disorders, especially schizophrenia and bipolar depression, leveraging novel mechanisms for CNS conditions.
Weight: 88
Acquired Karuna Therapeutics, gaining a late-stage schizophrenia drug (KarXT) that directly competes with existing or pipeline treatments for psychosis.
Weight: 86
Focuses on developing and commercializing therapies for schizophrenia, bipolar I disorder, and depression, with a strong presence in the CNS space.